Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus

Launched by IMPERIAL COLLEGE LONDON · Jun 12, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at how continuing standard diabetes medications after bariatric surgery may help people with Type 2 diabetes manage their condition better in the long run. Typically, after surgery, doctors stop all diabetes medications and only restart them if diabetes symptoms come back. However, many patients who initially see improvements end up experiencing a return of their diabetes within five years. This study aims to find out if keeping patients on their medications after surgery is safe and can lead to better health outcomes.

To participate in this trial, individuals need to be eligible for bariatric surgery and have Type 2 diabetes with a body mass index (BMI) over 30. There are some exclusions, such as recent hospital stays or if someone has had bariatric surgery before. Participants will be monitored to see how they respond to continuing medication after their surgery, helping researchers understand the best approach for managing diabetes post-surgery. If you're considering bariatric surgery and have Type 2 diabetes, this study might be a valuable opportunity to help improve future care for yourself and others.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • eligible for bariatric surgery according to NICE guidelines (GC 189)
• • Type 2 diabetes mellitus
• • BMI \>30kg/m2
• Exclusion Criteria:
• • Recent hospitalisation in the past 30 days
• • Recurrent hypoglycaemic episodes
• • Recurrent hypotensive episodes
• • Contraindications to bariatric surgery
• • Previous bariatric surgery
• • Current pregnancy
• • Breastfeeding